Back to Stakeholders
Specialized Academic Departments and InstitutesIndependent Academic Research Groups

University of Amsterdam

Netherlands
27 Trials

The University of Amsterdam (UvA) is one of the Netherlands' leading research universities, with its Amsterdam UMC Department of Psychiatry conducting clinical trials on psilocybin and psychedelic-assisted therapies for treatment-resistant mental health conditions.

Quick Facts

Type
Other
HQ
Netherlands
Website
Visit

Sponsored Trials

20
RecruitingIII

Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)

Start Date
Compounds
Placebo, Ketamine
Not yet recruitingII

Ketamine-Assisted Psychotherapy for Treatment-Resistant Depression

Start Date
Compounds
Ketamine
Not yet recruitingII

Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence (PsiPTSD)

Start Date
Compounds
Psilocybin
RecruitingI

Drug Effects on Mood and Behavior – Expectancy (MESA-X)

Start Date
Compounds
LSD, Placebo
Not yet recruitingI

Psilocybin for Prolonged Grief Disorder

Start Date
Compounds
Psilocybin
Not yet recruitingII

Stress Experience Following Psilocybin (SEP-1)

Start Date
Compounds
Psilocybin, Placebo
Enrolling by invitationNA

Cognitive Training as an Adjunct to Ketamine in Real-world Clinics

Start Date
RecruitingI

Treatment of Persistent Post-concussive Symptoms With Psilocybin Assisted Therapy (PatACT)

Start Date
Compounds
Psilocybin
CompletedNA

(GluEsk) Glutamate and Esketamine (GluEsk)

Start Date
Compounds
Esketamine, Placebo
RecruitingII

Psilocybin vs Ketamine for Alcohol Use Disorder (Psi vs Ket)

Start Date
Compounds
Psilocybin, Ketamine
RecruitingII

Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder (PAP-AUD)

Start Date
Compounds
Psilocybin
RecruitingNA

Effect of Psychedelic VR-augmented Therapy on Patients With Clinical Depression

Start Date
TerminatedI

Ketamine-assisted Psychotherapy (KAP) for Patients With Existential Distress Associated With Non-operable GI Cancers

Start Date
Compounds
Ketamine
CompletedI

Prosocial Effects of MDMA (PEM)

Start Date
Compounds
Placebo, MDMA
Unknown statusIII

Study of IV Ketamine for Emergency Department Treatment of Adolescent Suicidal Ideation

Start Date
Compounds
Ketamine, Placebo
RecruitingNA

Metabolic Profiling of Esketamine Treatment in Depressive Disorder

Start Date
Compounds
Esketamine
Temporarily not availableNA

Testing the Effectiveness of Cognitive Training Among Depressed Patients Receiving Esketamine Treatment

Start Date
CompletedI

PAPR: PAP + MBSR for Front-line Healthcare Provider COVID-19 Related Burnout (PAPR)

Start Date
Compounds
Psilocybin
CompletedNA

Psilocybin-assisted Interpersonal and Social Rhythm Therapy for Depression

Start Date
Compounds
Psilocybin
CompletedII

Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder

Start Date
Compounds
Psilocybin

Collaborated Trials

7
Not yet recruitingII

Targeting Treatment-Resistant OUD With Ketamine-Assisted Mindfulness Oriented Recovery Enhancement

Start Date
Compounds
Ketamine, Placebo
Not yet recruitingI

KF2024#1-trial: Esketamine Interaction Study

Start Date
Compounds
Esketamine, Placebo
Not yet recruitingII

Psilocybin-Assisted Cognitive Processing Therapy for Chronic PTSD

Start Date
Compounds
Psilocybin
Enrolling by invitationIV

Comparative Effectiveness of ECT vs. KETAMINE Over the Lifespan (REaKT-SD)

Start Date
Compounds
Ketamine, Placebo
WithdrawnI

Mood and Cognitive Effects of Psilocybin in Healthy Participants (MELO)

Start Date
Compounds
Placebo, Psilocybin
RecruitingIV

Ketamine in Acute Brain Injury Patients

Start Date
Compounds
Ketamine, Placebo
CompletedI

Study Where Pharmaco Magnetic Resonance Imaging (MRI) Effects of AZD6765 Will be Compared to Placebo in Depressive Male and Female Subjects

Start Date
Compounds
Placebo, Ketamine